Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Neuroreport ; 11(2): 405-8, 2000 Feb 07.
Article in English | MEDLINE | ID: mdl-10674495

ABSTRACT

Presenilin (PS) mutations are associated with early-onset Alzheimer's disease and PS proteins are involved with gamma-secretase cleavage of the amyloid precursor protein, APP. We have shown previously that alpha-, beta- and gamma-secretase cleavages of APP are conserved in Pichia pastoris. Here, we report co-expression of APP and PSI in P. pastoris and show by immunoelectron microscopy colocalization of these two proteins in expanded endoplasmic reticulum. Western blot analysis indicates a drastic reduction of both alpha- and beta-secretase products. A relative increase in beta-secretase product derived from immature APP is also observed, pointing to a beta-secretase activity of P. pastoris associated with the early secretory pathway.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Membrane Proteins/biosynthesis , Membrane Proteins/genetics , Pichia/enzymology , Pichia/genetics , Amyloid Precursor Protein Secretases , Amyloid beta-Protein Precursor/biosynthesis , Amyloid beta-Protein Precursor/genetics , Aspartic Acid Endopeptidases/metabolism , Blotting, Western , Clone Cells/cytology , Clone Cells/enzymology , Clone Cells/metabolism , Endopeptidases , Endoplasmic Reticulum/metabolism , Glycosylation , Immunohistochemistry , Microscopy, Electron , Models, Biological , Pichia/cytology , Pichia/ultrastructure , Presenilin-1 , Protein Processing, Post-Translational , Transfection
2.
Nat Struct Biol ; 6(4): 327-31, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10201399

ABSTRACT

Amyloid precursor protein (APP) plays a central role in Alzheimer disease. A proteolytic-breakdown product of APP, called beta-amyloid, is a major component of the diffuse and fibrillar deposits found in Alzheimer diseased brains. The normal physiological role of APP remains largely unknown despite much work. A knowledge of its function will not only provide insights into the genesis of the disease but may also prove vital in the development of an effective therapy. Here we describe the 1.8 A resolution crystal structure of the N-terminal, heparin-binding domain of APP (residues 28-123), which is responsible, among other things, for stimulation of neurite outgrowth. The structure reveals a highly charged basic surface that may interact with glycosaminoglycans in the brain and an abutting hydrophobic surface that is proposed to play an important functional role such as dimerization or ligand binding. Structural similarities with cysteine-rich growth factors, taken together with its known growth-promoting properties, suggests the APP N-terminal domain could function as a growth factor in vivo.


Subject(s)
Amyloid beta-Protein Precursor/chemistry , Amyloid beta-Protein Precursor/metabolism , Alzheimer Disease/metabolism , Amino Acid Sequence , Binding Sites , Crystallography, X-Ray , Growth Substances/chemistry , Heparin/metabolism , Hepatocyte Growth Factor/chemistry , Models, Molecular , Molecular Sequence Data , Peptide Fragments/chemistry , Protein Conformation , Sequence Homology, Amino Acid
3.
FEBS Lett ; 442(1): 95-8, 1999 Jan 08.
Article in English | MEDLINE | ID: mdl-9923612

ABSTRACT

The human amyloid precursor-like protein 2 (APLP2) is a member of the Alzheimer's disease amyloid precursor protein (APP) gene family. The human APLP2 ectodomain (sAPLP2) was expressed in the yeast Pichia pastoris and the recombinant sAPLP2 was purified from the culture medium in a single step by metal-chelating Sepharose chromatography. The neuritotrophic activity of APLP2 was compared to the APP isoforms sAPP695 and sAPP751 on chick sympathetic neurones. APLP2 had neurite outgrowth-promoting activity similar to that of the APP isoforms. This suggests that APP and APLP2 have a similar or related role and supports the idea of a redundancy in function between the APP-gene family proteins.


Subject(s)
Amyloid beta-Protein Precursor/pharmacology , Nerve Tissue Proteins/pharmacology , Neurites/drug effects , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/physiology , Animals , Base Sequence , Chickens , DNA Primers/genetics , Ganglia, Sympathetic/drug effects , Ganglia, Sympathetic/growth & development , Gene Expression , Humans , In Vitro Techniques , Mice , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/physiology , Pichia/genetics , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/pharmacology
4.
Br J Haematol ; 103(2): 402-15, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9827912

ABSTRACT

The amyloid precursor protein (APP) of Alzheimer's disease is abundantly expressed in the platelet alpha-granule where its role remains unclear. This study describes a novel function for APP in regulating human platelet activation. Preincubation of platelet-rich plasma with recombinant secreted APP (sAPP) isoforms dose-dependently inhibited platelet aggregation and secretion induced by ADP or adrenaline. Similarly, sAPP potently inhibited low-dose thrombin-induced activation in washed platelet suspensions, indicating that the activity does not require plasma cofactors. There were no functional differences between sAPP forms with or without the Kunitz protease inhibitor domain or derived from either alpha- or beta-secretase cleavage. In fact, the N-terminal cysteine-rich region of APP (residues 18-194) was as effective as the entire sAPP region in the inhibition of platelet activation. The inhibitory activity of sAPP correlated with a significant reduction in the agonist-induced production of the arachidonic acid (AA) metabolites thromboxane B2 and prostaglandin E2. However, sAPP did not affect AA-induced platelet aggregation or secretion, indicating the enzymatic conversion of AA was not inhibited. The addition of a threshold dose of AA reversed the sAPP-inhibition of agonist-induced platelet activation. This suggests that sAPP decreases the availability of free AA, although the mechanism is not yet known. These data provide evidence that the release of sAPP upon platelet degranulation may result in negative feedback regulation during platelet activation.


Subject(s)
Alzheimer Disease/blood , Amyloid beta-Protein Precursor/pharmacology , Platelet Activation/drug effects , Adenosine Diphosphate/antagonists & inhibitors , Amyloid beta-Protein Precursor/chemistry , Arachidonic Acid/pharmacology , Cell Culture Techniques , Dinoprostone/biosynthesis , Dose-Response Relationship, Drug , Epinephrine/antagonists & inhibitors , Humans , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/pharmacology , Recombinant Proteins/pharmacology , Structure-Activity Relationship , Thrombin/antagonists & inhibitors , Thromboxane B2/biosynthesis
5.
Biochemistry ; 37(42): 14958-65, 1998 Oct 20.
Article in English | MEDLINE | ID: mdl-9778373

ABSTRACT

betaA4 (Abeta) amyloid peptide, a major component of Alzheimer's disease (AD) plaques, is a proteolytic product of the amyloid precursor protein (APP). Endoproteases, termed beta- and gamma-secretase, release respectively the N- and C-termini of the peptide. APP default secretion involves cleavage within the betaA4 domain by alpha-secretase. To study the conservation of APP processing in lower eukaryotes, the yeast Pichia pastoris was transfected with human APP695 cDNA. In addition to the full-length integral transmembrane protein found in the cell lysate, soluble/secreted APP (sAPP) was detected in the culture medium. Most sAPP comprised the N-terminal moiety of betaA4 and corresponds to sAPPalpha, the product of alpha-secretase. The culture medium also contained minor secreted forms detected by a monoclonal antibody specific for sAPPbeta (the ectodomain released by beta-secretase cleavage). Analysis of the cell lysates with specific antibodies also detected membrane-associated C-terminal fragments corresponding to the products of alpha and beta cleavages. Moreover, immunoprecipitation of the culture medium with three antibodies directed at distinct epitopes of the betaA4 domain yielded a 4 kDa product with the same electrophoretic mobility as betaA4 synthetic peptide. These results suggest that the alpha-, beta-, and gamma-secretase cleavages are conserved in yeast and that P. pastoris may offer an alternative to mammalian cells to identify the proteases involved in the generation of AD betaA4 amyloid.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/metabolism , Endopeptidases/metabolism , Pichia/genetics , Pichia/metabolism , Protein Processing, Post-Translational , Amyloid Precursor Protein Secretases , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/immunology , Aspartic Acid Endopeptidases , Blotting, Western , Cloning, Molecular , Endopeptidases/immunology , Humans , Hydrolysis , Neuroblastoma , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Precipitin Tests , Protein Processing, Post-Translational/genetics , Recombinant Proteins/immunology , Recombinant Proteins/metabolism , Tumor Cells, Cultured
6.
J Neurosci ; 18(16): 6207-17, 1998 Aug 15.
Article in English | MEDLINE | ID: mdl-9698314

ABSTRACT

Studies on the amyloid precursor protein (APP) have suggested that it may be neuroprotective against amyloid-beta (Abeta) toxicity and oxidative stress. However, these findings have been obtained from either transfection of cell lines and mice that overexpress human APP isoforms or pretreatment of APP-expressing primary neurons with exogenous soluble APP. The neuroprotective role of endogenously expressed APP in neurons exposed to Abeta or oxidative stress has not been determined. This was investigated using primary cortical and cerebellar neuronal cultures established from APP knock-out (APP-/-) and wild-type (APP+/+) mice. Differences in susceptibility to Abeta toxicity or oxidative stress were not found between APP-/- and APP+/+ neurons. This observation may reflect the expression of the amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2) molecules and supports the theory that APP and the APLPs may have similar functional activities. Increased expression of cell-associated APLP2, but not APLP1, was detected in Abeta-treated APP-/- and APP+/+ cultures but not in H2O2-treated cultures. This suggests that the Abeta toxicity pathway differs from other general forms of oxidative stress. These findings show that Abeta toxicity does not require an interaction of the Abeta peptide with the parental molecule (APP) and is therefore distinct from prion protein neurotoxicity that is dependent on the expression of the parental cellular prion protein.


Subject(s)
Amyloid beta-Peptides/poisoning , Amyloid beta-Protein Precursor/genetics , Mice, Knockout/genetics , Neurons/drug effects , Neurons/physiology , Oxidative Stress/physiology , Alzheimer Disease/metabolism , Amyloid beta-Peptides/pharmacology , Amyloid beta-Protein Precursor/analogs & derivatives , Amyloid beta-Protein Precursor/metabolism , Amyloid beta-Protein Precursor/pharmacology , Animals , Cell Survival/physiology , Cells, Cultured , Cerebellum/cytology , Cerebellum/drug effects , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Fibroblast Growth Factor 2/pharmacology , Glutamic Acid/pharmacology , Hydrogen Peroxide/pharmacology , Mice , Mice, Inbred C57BL , Peptide Fragments/pharmacology , Superoxides/pharmacology
7.
Amyloid ; 5(2): 79-89, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9686302

ABSTRACT

Different isoforms and derived polypeptides of the Alzheimer's disease amyloid protein precursor (A beta PP) have been expressed in the yeast Pichia pastoris. The expression characteristics of the different A beta PP polypeptides were studied by post-embedding immunogold electron microscopy with various A beta PP antibodies. The site of intracellular expression could be readily identified with specific antibodies. Full length A beta PP was expressed in association with the nuclear membrane and the endoplasmic reticulum. Secretory derivatives of A beta PP were localized in membrane-bound secretory vesicles. A construct encoding two copies of beta A4[1-42] linked head-to-tail (beta A4duplex) accumulated as irregular dense cytoplasmic and intranuclear inclusions which reacted with all beta A4 antibodies tested. A beta A4-C-terminal construct accumulated into membranous structures in the cytoplasm and nucleus and reacted with most antibodies to beta A4 and the cytoplasmic domain of A beta PP. The two shorter constructs containing the beta A4 sequence formed similar intranuclear aggregates to those reported for intranuclear inclusions of polyglutamine peptides from huntingtin (in Huntington's disease) and ataxin protein fragments (in spinocerebellar ataxia). This is of interest because intracellular aggregation of the polyglutamine and beta A4 peptides may affect cells by similar toxic mechanisms. These studies demonstrate clear differences in the expression properties of different A beta PP polypeptides.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/genetics , Peptides/genetics , Subcellular Fractions/chemistry , Amyloid beta-Protein Precursor/biosynthesis , Humans , Immunohistochemistry , Microscopy, Immunoelectron , Peptides/metabolism , Pichia , Recombinant Proteins/biosynthesis
8.
FEBS Lett ; 415(3): 303-7, 1997 Oct 06.
Article in English | MEDLINE | ID: mdl-9357988

ABSTRACT

Deletion mutagenesis studies have suggested that there are two domains within APP which bind heparan sulphate. These domains have been cloned and expressed in the yeast Pichia pastoris. Both recombinant proteins bound to heparin. One domain (APP316-447) was further characterised by binding studies with peptides encompassing this region. Peptides homologous to APP316-346 and APP416-447 were found to bind heparin. Circular dichroism studies show that APP416-447 shifted towards an alpha-helical conformation in the presence of heparin. This study suggests that heparin-binding domains may lie within regions high in alpha-helical structure.


Subject(s)
Amyloid beta-Protein Precursor/genetics , Heparin/metabolism , Protein Structure, Secondary , Alzheimer Disease , Amyloid beta-Protein Precursor/chemistry , Binding Sites , Blotting, Western , Chromatography, Affinity , Circular Dichroism , Cloning, Molecular , Escherichia coli/genetics , Gene Expression , Humans , Mutagenesis , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/metabolism , Protein Binding , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Sequence Deletion
9.
Mol Biochem Parasitol ; 82(2): 181-94, 1996 Nov 25.
Article in English | MEDLINE | ID: mdl-8946384

ABSTRACT

A photoreactive quinolinemethanol analog, N-[4-[1-hydroxy-2-(dibutylamino)ethyl]quinolin-8yl]-4- azido-2-salicylamide (ASA-MQ) has been synthesized which closely mimics the action of mefloquine. ASA-MQ possesses potent antimalarial activity against a mefloquine-sensitive strain of Plasmodium falciparum and shows decreased activity against a mefloquine-resistant parasite strain. Radioiodinated ASA-MQ has been used in photoaffinity labeling studies to identify mefloquine-interacting proteins in serum, uninfected erythrocytes and Plasmodium falciparum-infected erythrocytes. We have shown that mefloquine interacts specifically with apo-A1, the major protein of serum high density lipoproteins. In addition, mefloquine was shown to interact specifically with the erythrocyte membrane protein, band 7.2b (stomatin). A further two high affinity mefloquine-binding proteins with apparent molecular masses of 22 and 36 kDa were identified in three different strains of Plasmodium falciparum. We suggest that these two mefloquine-binding parasite proteins may be involved in the uptake of mefloquine or may represent macromolecular targets of mefloquine action in malaria parasites.


Subject(s)
Antimalarials/metabolism , Blood Proteins/metabolism , Mefloquine/metabolism , Membrane Proteins , Plasmodium falciparum/metabolism , Protozoan Proteins/metabolism , Affinity Labels , Animals , Apolipoprotein A-I/metabolism , Drug Resistance , Erythrocyte Membrane/metabolism , Humans , Mefloquine/analogs & derivatives , Mefloquine/pharmacology
10.
Exp Parasitol ; 83(3): 295-303, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8823246

ABSTRACT

Amplification and overexpression of the pfmdr1 gene has been associated with mefloquine resistance in Plasmodium falciparum. We have selected for parasites more resistant to mefloquine from P. falciparum FAC8, a clone that has three copies of pfmdr1. The parasite lines derived from this selection were up to threefold more resistant to mefloquine. The mefloquine-selected parasites were also more resistant to quinine and halofantrine, suggesting a multidrug resistance phenotype. In contrast to previous findings, the selection of P. falciparum FAC8 on mefloquine did not alter the copy number or the level of expression of pfmdr1. Sequence analysis of pfmdr1 from the selected lines showed no change in the amino acids. These results show that alterations in pfmdr1 are not involved in mediating the increased mefloquine resistance observed in this clone.


Subject(s)
ATP-Binding Cassette Transporters , Antimalarials/pharmacology , Gene Amplification , Mefloquine/pharmacology , Plasmodium falciparum/drug effects , Protozoan Proteins/genetics , Animals , DNA, Protozoan/analysis , DNA, Protozoan/genetics , Drug Resistance, Multiple/genetics , Gene Dosage , Gene Expression Regulation , Genes, Protozoan , Plasmodium falciparum/genetics , Protozoan Proteins/analysis , Sequence Analysis, DNA , Verapamil/pharmacology
11.
J Med Chem ; 38(1): 204-6, 1995 Jan 06.
Article in English | MEDLINE | ID: mdl-7837232

ABSTRACT

A new type of bisquinoline antimalarial, in which the basic side chain of chloroquine is retained, has been evaluated. Nine bisamides were prepared from aliphatic diacids with 6-amino- and 8-amino-((4-(diethylamino)-1-methylbutyl)amino)quinoline, and screened against chloroquine-sensitive and -resistant strains of Plasmodium falciparum in vitro. The resistance indices for all compounds were lower than for chloroquine. The position of attachment and length of the linker chain markedly affected activity. The most active (IC50 = 120 nM against the chloroquine-resistant FAC8 strain) was the -(O)C(CH2)4C(O)- linked 8-amino compound.


Subject(s)
Antimalarials/chemical synthesis , Antimalarials/pharmacology , Quinolines/chemical synthesis , Quinolines/pharmacology , Animals , Chloroquine/analogs & derivatives , Plasmodium falciparum/drug effects
12.
Proc Natl Acad Sci U S A ; 91(3): 1143-7, 1994 Feb 01.
Article in English | MEDLINE | ID: mdl-8302844

ABSTRACT

Two chloroquine-resistant cloned isolates of Plasmodium falciparum were subjected to mefloquine selection to test if this resulted in alterations in chloroquine sensitivity and amplification of the pfmdr1 gene. The mefloquine-resistant lines derived by this selection were shown to have amplified and overexpressed the pfmdr1 gene and its protein product (Pgh1). Macrorestriction maps of chromosome 5, where pfmdr1 is encoded, showed that this chromosome has increased in size in response to mefloquine selection, indicating the presence of a gene(s) in this area of the genome that confers a selective advantage in the presence of mefloquine. Concomitant with the increase in mefloquine resistance was a corresponding increase in the level of resistance to halofantrine and quinine, suggesting a true multidrug-resistance phenotype. The mefloquine-selected parasite lines also showed an inverse relationship between the level of chloroquine resistance and increased pfmdr1 gene copy number. These results have important implications for the derivation of amplified copies of the pfmdr1 gene in field isolates, as they suggest that quinine pressure may be involved.


Subject(s)
Mefloquine/pharmacology , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Animals , Chromosome Mapping , Drug Resistance/genetics , Gene Amplification , Gene Expression , Genes, Protozoan , Humans , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Phenanthrenes/pharmacology , Plasmodium falciparum/isolation & purification , Quinine/pharmacology
13.
Mol Biochem Parasitol ; 58(2): 269-76, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8097560

ABSTRACT

The Plasmodium falciparum P-glycoprotein homologue 1 (PGH1) is structurally similar to several members of the ATP-binding cassette (ABC) superfamily of membrane transporters. We have examined whether the nucleotide binding domains predicted from the deduced amino sequence are functional by photoaffinity labeling of purified parasite digestive vacuoles with the analogue 8-azido-alpha-[32P]ATP (8-N3-ATP). This reagent labels a 160-kDa protein in vacuoles from both a chloroquine sensitive and a chloroquine-resistant parasite isolate. The 160-kDa protein could be immunoprecipitated with affinity-purified antibodies against the P. falciparum P-glycoprotein homologue (PGH1). Inhibition of photoaffinity labeling of PGH1 could be achieved with ATP, ADP, GTP and GDP but not with AMP or GMP. In order to map the 8-N3-ATP binding sites on PGH1, photoaffinity-labeled PGH1 was digested with trypsin and immunoprecipitated with site-specific antibodies. Taken together, these results indicate that 8-N3-ATP specifically labels PGH1 and that one binding site resides within the amino terminal half of the molecule. This supports the contention that PGH1 is involved in a nucleotide-regulated transport function across the membrane of the digestive vacuole.


Subject(s)
Membrane Glycoproteins/metabolism , Nucleotides/metabolism , Plasmodium falciparum/metabolism , Protozoan Proteins/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/metabolism , Affinity Labels , Animals , Azides/metabolism , Binding Sites , Carrier Proteins/chemistry , Carrier Proteins/metabolism , Membrane Glycoproteins/chemistry , Molecular Weight , Protozoan Proteins/chemistry , Vacuoles/metabolism
14.
EMBO J ; 11(8): 3067-75, 1992 Aug.
Article in English | MEDLINE | ID: mdl-1353446

ABSTRACT

A chloroquine resistant cloned isolate of Plasmodium falciparum, FAC8, which carries an amplification in the pfmdr1 gene was selected for high-level chloroquine resistance, resulting in a cell line resistant to a 10-fold higher concentration of chloroquine. These cells were found to have lost the amplification in pfmdr1 and to no longer over-produce the protein product termed P-glycoprotein homologue 1 (Pgh1). The pfmdr1 gene from this highly resistant cell line was not found to encode any amino acid changes that would account for increased resistance. Verapamil, which reverses chloroquine resistance in FAC8, also reversed high-level chloroquine resistance. Furthermore, verapamil caused a biphasic reversal of chloroquine resistance as the high-level resistance was very sensitive to low amounts of verapamil. These data suggest that over-expression of the P-glycoprotein homologue is incompatible with high levels of chloroquine resistance. In order to show that these results were applicable to other chloroquine selected lines, two additional mutants were selected for resistance to high levels of chloroquine. In both cases they were found to deamplify pfmdr1. Interestingly, while the level of chloroquine resistance of these mutants increased, they became more sensitive to mefloquine. This suggests a linkage between the copy number of the pfmdr1 gene and the level of chloroquine and mefloquine resistance.


Subject(s)
Chloroquine/pharmacology , Drug Resistance/genetics , Mefloquine/pharmacology , Plasmodium falciparum/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Animals , Chromosome Deletion , Chromosome Mapping , Dose-Response Relationship, Drug , Gene Amplification , Membrane Glycoproteins/genetics , Plasmodium falciparum/drug effects , Plasmodium falciparum/growth & development , Restriction Mapping , Verapamil/pharmacology
15.
Exp Parasitol ; 73(3): 269-75, 1991 Oct.
Article in English | MEDLINE | ID: mdl-1915742

ABSTRACT

The in vitro growth of Plasmodium falciparum is sensitive to some calmodulin antagonists and these compounds show antagonism with classic antimalarials such as chloroquine suggesting competition for the same drug binding site. In order to ask if calmodulin is involved in resistance to chloroquine we cloned the calmodulin gene of P. falciparum. We show that it is encoded by a single gene and that the putative protein is highly homologous to calmodulin from other eukaryotes. The calmodulin gene is encoded on chromosome 14 and contains a single intron of 506 bp that has the appropriate donor and acceptor splice sites. Two major transcripts of similar size are encoded by this gene. The sequence of the gene is identical and the calmodulin protein is expressed approximately equally in chloroquine resistant and sensitive isolates of P. falciparum suggesting that alterations in this protein play no role in the mechanism of chloroquine resistance in the isolates tested.


Subject(s)
Calmodulin/genetics , Chloroquine/pharmacology , Gene Expression , Plasmodium falciparum/genetics , Amino Acid Sequence , Animals , Base Sequence , Calmodulin/biosynthesis , Chromosome Mapping , DNA, Protozoan/genetics , Drug Resistance , Gene Amplification , Genes , Molecular Sequence Data , Plasmodium falciparum/drug effects , Transcription, Genetic
16.
J Cell Biol ; 113(5): 1033-42, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1674943

ABSTRACT

Resistance to chloroquine in Plasmodium falciparum bears a striking similarity to the multi-drug resistance (MDR) phenotype of mammalian tumor cells which is mediated by overexpression of P-glycoprotein. We show here that the P. falciparum homologue of the P-glycoprotein (Pgh1) is a 160,000-D protein that is expressed throughout the asexual erythrocytic life cycle of the parasite. Quantitative immunoblotting analysis has shown that the protein is expressed at approximately equal levels in chloroquine resistant and sensitive isolates suggesting that overexpression of Pgh1 is not essential for chloroquine resistance. The chloroquine-resistant cloned line FAC8 however, does express approximately threefold more Pgh1 protein than other isolates which is most likely because of the increased pfmdr1 gene copy number present in this isolate. Immunofluorescence and immunoelectron microscopy has demonstrated that Pgh1 is localized on the membrane of the digestive vacuole of mature parasites. This subcellular localization suggests that Pgh1 may modulate intracellular chloroquine concentrations and has important implications for the normal physiological function of this protein.


Subject(s)
Chloroquine/pharmacology , Membrane Glycoproteins/analysis , Plasmodium falciparum/physiology , Vacuoles/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Animals , Digestion , Drug Resistance , Electrophoresis, Polyacrylamide Gel , Fluorescent Antibody Technique , Immunoblotting , Membrane Glycoproteins/genetics , Microscopy, Immunoelectron , Molecular Weight , Plasmodium falciparum/drug effects , Plasmodium falciparum/ultrastructure , Vacuoles/ultrastructure
17.
Proc Natl Acad Sci U S A ; 87(8): 3014-7, 1990 Apr.
Article in English | MEDLINE | ID: mdl-2183221

ABSTRACT

Cycloguanil, the active metabolite of the antimalarial drug proguanil, is an inhibitor of dihydrofolate reductase as is another antimalarial, pyrimethamine. Its use has been limited by the rapid development of resistance by parasites around the world. We have determined the cycloguanil- and pyrimethamine-sensitivity status of 10 isolates of Plasmodium falciparum and have sequenced in all these isolates the dihydrofolate reductase (DHFR; 5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, EC 1.5.1.3) portion of the DHFR-thymidylate synthase (TS; 5,10-methylenetetrahydrofolate: dUMP C-methyltransferase, EC 2.1.1.45) gene. Instead of the known serine-to-asparagine change at position 108 that is important in pyrimethamine resistance, a serine-to-threonine change at the same position is found in cycloguanil-resistant isolates along with an alanine-to-valine change at position 16. We conclude that pyrimethamine and cycloguanil resistance most commonly involve alternative mutations at the same site. However, we also have identified a parasite with a unique set of changes that results in resistance to both drugs.


Subject(s)
Genes , Plasmodium falciparum/genetics , Pyrimethamine/pharmacology , Tetrahydrofolate Dehydrogenase/genetics , Thymidylate Synthase/genetics , Triazines/pharmacology , Amino Acid Sequence , Animals , Base Sequence , DNA/genetics , DNA/isolation & purification , Drug Resistance/genetics , Molecular Sequence Data , Oligonucleotide Probes , Plasmodium falciparum/drug effects , Plasmodium falciparum/enzymology , Proguanil
SELECTION OF CITATIONS
SEARCH DETAIL
...